Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Lucigen Corporation and Research Corporation Technologies Announce Partnership

Published: Thursday, May 02, 2013
Last Updated: Thursday, May 02, 2013
Bookmark and Share
Partnership to commercialize and distribute the CleanColi™ Expression System, the first Escherichia coli (E. coli)-based recombinant system that lacks unwanted endotoxin.

Lucigen will produce and sell kits containing CleanColi™ competent cells and provide contract research services for the CleanColi™ Expression System. Lucigen simultaneously announces the release of a CleanColi™ competent cell line enabling the production of proteins virtually free of endotoxin contamination, thereby minimizing purification and allowing faster and more accurate screening of biological targets for drug discovery research. Under the partnership, RCT will be responsible for the CleanColi™ commercial licensing programs.

Drug discovery researchers are increasingly turning to biologics as the source for new therapeutics, utilizing the incredible diversity of proteins in order to find new treatments for disease. To synthesize and manipulate these proteins, researchers normally insert genes coding for the desired protein into mammalian, yeast, or bacterial cells. The common bacteria E. coli is a widely used system for expression of recombinant proteins, but this method has the disadvantage that, without time-consuming and expensive cleanup, it produces contaminating endotoxin that kills human cells. Failure to remove endotoxin from the final product can result in false or misleading results, potentially causing a researcher to improperly reject a promising drug candidate.

Lucigen and RCT have developed the CleanColi™ competent cell strain for protein expression. This new strain has a genetically modified lipopolysaccharide (LPS) that does not cause an endotoxic response in human cells. By producing proteins without contaminating endotoxin, researchers can increase productivity by reducing the time, cost, and loss of product associated with endotoxin removal. More important, cell-based assays can be performed without concern that LPS (endotoxin) contamination could be masking promising results. Researchers can accelerate drug discovery research and ensure the most accurate results possible. Additional cell lines for plasmid production and phage display are also planned for release, creating a complete system for scientists to study a large variety of biologic compounds for therapeutic applications.

“E. coli is commonly used for research scale protein expression but its ease of use has been limited by unwanted endotoxin contamination. These days are hopefully over. RCT and their collaborators have developed technology allowing for the creation of the first viable E.coli strains lacking endotoxin in the membrane. The CleanColi™ cell lines will accelerate how researchers screen novel compounds for drug discovery. By eliminating the source of endotoxin, scientists can increase the number of compounds screened and more accurately pinpoint candidates for further testing. We are proud to work with RCT to introduce this truly novel system to the world,” states David Mead, Ph.D., Lucigen founder and CEO.

“Lucigen is the ideal partner to launch the CleanColi™ Expression System. They have established themselves as the clear market leader for high efficiency competent cells. We are looking forward to working with them and future licensees of the CleanColi™ Expression System to bring this valuable tool to commercial research and recombinant protein production,” said Chad Souvignier, Ph.D., Managing Director at RCT.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Lucigen, Thermo Fisher to Release New Mate Pair Library Technology
The Ion PGM is a fast and cost-effective platform for next generation sequencing applications.
Wednesday, August 27, 2014
Scientific News
Improving Natural Killer Cancer Therapy
Vanderbilt University researchers discover transcription factor critical for NK cell expansion. Findings could lead to increased therapeutic efficacy.
Molecular Mechanism For Generating Specific Antibody Responses Discovered
Study could spur more ways to treat autoimmune disease, develop accurate vaccines.
Monovar Drills Down Into Cancer Genome
Rice, MD Anderson develop program to ID mutations in single cancer cells.
It’s Now Easier To Go With The Flow
Rice University tool simplifies comparison of flow cytometry data for laboratories.
Autism and Cancer Share a Remarkable Number of Risk Genes
Researchers with the UC Davis Comprehensive Cancer Center, MIND Institute identify more than 40 common genes.
Number Of Known Genetic Risk Factors For Endometrial Cancer Doubled
An international collaboration of researchers has identified five new gene regions that increase a woman’s risk of developing endometrial cancer, one of the most common cancers to affect women, taking the number of known gene regions associated with the disease to nine.
Genetic Variant May Help Explain Why Labradors Are Prone To Obesity
A genetic variation associated with obesity and appetite in Labrador retrievers – the UK and US’s favourite dog breed – has been identified by scientists at the University of Cambridge. The finding may explain why Labrador retrievers are more likely to become obese than dogs of other breeds.
FNIH Launches Project to Evaluate Biomarkers in Cancer Patients
Company has announced that it has launched a new project to evaluate the effectiveness of liquid biopsies as biomarkers in colorectal cancer patients.
Flowering Regulation Mechanism Discovered
Monash researchers have discovered a new mechanism that enables plants to regulate their flowering in response to raised temperatures.
Turning Skin Cells into Heart, Brain Cells
In a major breakthrough, scientists at the Gladstone Institutes transformed skin cells into heart cells and brain cells using a combination of chemicals.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!